Heartburn treatment in primary care: randomised, double blind study for 8 weeksBMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7209.550 (Published 28 August 1999) Cite this as: BMJ 1999;319:550
Sample size calculation
The sample size was calculated to be 160 patients per treatment arm, assuming 80% statistical power, a 5% significance level, and that the most efficacious treatment would result in adequate control of heartburn in 60% of patients after 4 weeks. A difference of 15% points between the treatments was considered clinically significant.
The participating primary care physicians in the Norwegian Heartburn Study Group were:Bjørn O Bache, Inger Bjurstrøm, Jens Brovold, Hans Braadland, Åge Dahl, Frode Flobak, Bjørn O Flaaten, Eivind Fristad, Olav Gaupen, Thomas Gladewitz, Ove Grønlie, Ole P Halvorsen, Åge N Hansen, Inge Haslerud, Henry Helvig, Kjell Hjelle, Bernt-H Høgsæt, Hans Høvik, Arne G Haanshuus, Harald Jomaas, Bjørg Jordet, Arild Kaisen, Odd E Karlsen, Alf Kimsås, Aslak N Knutsen, Pål Kristensen, Margarete Krog, Jan Laugen, Svein Lunde, Ingard Løge, Per H Madsen, Randi Medhus, Jan Melby, Geir Moe, Herman Myrland, Stein Nilsen, Tor Nilsen, Dag Nordhaug, Paal Norheim, Jostein Norvold, Per A Oppegaard, Mansour Parsi, Per Sandbakken, Robert Sillerud, Knut Spikkeland, Odd K Starheim, Ragnar Stene, Ragnhild Strand, Sigurd Thomle, Bernt E Tylden, Ivar H Udnæs, Jan-Richard Unnvik, Kolbjørn Valnes, Inger Viervoll Knoph, Hans B Visdal Johnsen, Audun Visted, Per O Walle, Erik L Werner, Ole A Ystgaard, and Anders O Aaserud. The participating gastroenterologists were: Ståle Barstad, Fred A Halvorsen, Jan G Hatlebakk, Kristian Hveem, Ole Høie, Gjermund Johnsen, Kjell Kannelønning, Bjørn Moum, Morten Mowé, and Tor M Omland.
Flow of participants through the trial
- This Week In The BMJ Published: 28 August 1999; BMJ 319 doi:10.1136/bmj.319.7209.0f
- Letter Published: 20 May 2000; BMJ 320 doi:10.1136/bmj.320.7246.1406
- Helen Salisbury: Talking about deathBMJ June 25, 2019, 365 l4346; DOI: https://doi.org/10.1136/bmj.l4346
- Vaccine safety: British are less sceptical than Europeans, but younger people need assuranceBMJ June 19, 2019, 365 l4291; DOI: https://doi.org/10.1136/bmj.l4291
- Helen Salisbury: Doctors’ duties in a fractured welfare stateBMJ June 18, 2019, 365 l4209; DOI: https://doi.org/10.1136/bmj.l4209
- Lack of training in eating disorders is contributing to avoidable deaths, MPs concludeBMJ June 18, 2019, 365 l4279; DOI: https://doi.org/10.1136/bmj.l4279
- Rammya Mathew: Infant feeding, informed choice, and shared decisionsBMJ June 13, 2019, 365 l4061; DOI: https://doi.org/10.1136/bmj.l4061
- Multimodal pain stimulations in patients with grade B oesophagitis
- Assessment of reflux symptom severity: methodological options and their attributes
- Helicobacter pylori infection and long term proton pump inhibitor therapy
- Management of uninvestigated dyspepsia: review and commentary
- How well is the clinical importance of study results reported? An assessment of randomized controlled trials
- Cisapride Decreases Gastroesophageal Reflux in Preterm Infants
- Management of gastro-oesophageal reflux disease in general practice
- No H pylori: less dyspepsia?
- Heartburn treatment in primary care
- Omeprazole was better than cisapride or placebo for controlling heartburn at 4 and 8 weeks
- Primary Care Treatment of Heartburn: Control Acid Production